{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:14:31Z","timestamp":1781756071502,"version":"3.54.5"},"reference-count":25,"publisher":"Norwegian Medical Association","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.20.1045","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T03:43:13Z","timestamp":1624938193000},"source":"Crossref","is-referenced-by-count":1,"title":["Diagnostikk og behandling av autoimmun hepatitt"],"prefix":"10.4045","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1493-2303","authenticated-orcid":false,"given":"Mette","family":"Vesterhus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Wiencke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Willy","family":"Haukeland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein Oskar","family":"Frigstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Normann","family":"Karlsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3693-7706","authenticated-orcid":false,"given":"Kristin Kaasen","family":"J\u00f8rgensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Folseraas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63: 971\u20131004. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26341719&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jhep.2015.06.030","DOI":"10.1016\/j.jhep.2015.09.016"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Mack\u00a0CL, Adams\u00a0D, Assis\u00a0DN et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases. Hepatology 2020; 72: 671\u2013722. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31863477&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fhep.31065","DOI":"10.1002\/hep.31065"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Boberg\u00a0KM, Aadland\u00a0E, Jahnsen\u00a0J et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99\u2013103. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9489916&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1080%2F00365529850166284","DOI":"10.1080\/00365529850166284"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Gr\u00f8nb\u00e6k\u00a0L, Vilstrup\u00a0H, Jepsen\u00a0P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014; 60: 612\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24326217&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jhep.2013.10.020","DOI":"10.1016\/j.jhep.2013.10.020"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Cook\u00a0GC, Mulligan\u00a0R, Sherlock\u00a0S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159\u201385. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4933363&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Foxfordjournals.qjmed.a067264","DOI":"10.1093\/oxfordjournals.qjmed.a067264"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Werner\u00a0M, Prytz\u00a0H, Ohlsson\u00a0B et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008; 43: 1232\u201340. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18609163&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1080%2F00365520802130183","DOI":"10.1080\/00365520802130183"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"van Gerven\u00a0NM, Verwer\u00a0BJ, Witte\u00a0BI et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014; 49: 1245\u201354. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25123213&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3109%2F00365521.2014.946083","DOI":"10.3109\/00365521.2014.946083"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Alvarez\u00a0F, Berg\u00a0PA, Bianchi\u00a0FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929\u201338. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10580593&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0168-8278(99)80297-9","DOI":"10.1016\/S0168-8278(99)80297-9"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Hennes\u00a0EM, Zeniya\u00a0M, Czaja\u00a0AJ et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169\u201376. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18537184&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fhep.22322","DOI":"10.1002\/hep.22322"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Lohse\u00a0AW. Recognizing autoimmune hepatitis: scores help, but no more. J Hepatol 2011; 54: 193\u20134. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21093949&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jhep.2010.07.013","DOI":"10.1016\/j.jhep.2010.07.013"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Czaja\u00a0AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009; 29: 816\u201323. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19018980&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fj.1478-3231.2008.01904.x","DOI":"10.1111\/j.1478-3231.2008.01904.x"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Lohse\u00a0AW, Sebode\u00a0M, J\u00f8rgensen\u00a0MH et al. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. J Hepatol 2020; 73: 1496\u2013506. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32707224&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jhep.2020.07.023","DOI":"10.1016\/j.jhep.2020.07.023"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Soloway\u00a0RD, Summerskill\u00a0WH, Baggenstoss\u00a0AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820\u201333. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4538724&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0016-5085(19)33223-8","DOI":"10.1016\/S0016-5085(19)33223-8"},{"key":"ref=14","unstructured":"Murray-Lyon\u00a0IM, Stern\u00a0RB, Williams\u00a0R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4121073&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0140-6736(73)92125-9"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Manns\u00a0MP, Woynarowski\u00a0M, Kreisel\u00a0W et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198\u2013206. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20600032&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1053%2Fj.gastro.2010.06.046","DOI":"10.1053\/j.gastro.2010.06.046"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Santiago\u00a0P, Schwartz\u00a0I, Tamariz\u00a0L et al. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther 2019; 49: 830\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30761563&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fapt.15157","DOI":"10.1111\/apt.15157"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Roberts\u00a0SK, Lim\u00a0R, Strasser\u00a0S et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy. Clin Gastroenterol Hepatol 2018; 16: 268\u201377. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29050991&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.cgh.2017.09.063","DOI":"10.1016\/j.cgh.2017.09.063"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Sharzehi\u00a0K, Huang\u00a0MA, Schreibman\u00a0IR et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010; 24: 588\u201392. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21037986&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1155%2F2010%2F891252","DOI":"10.1155\/2010\/891252"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Zachou\u00a0K, Gatselis\u00a0N, Papadamou\u00a0G et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na\u00efve patients. J Hepatol 2011; 55: 636\u201346. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21238519&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jhep.2010.12.032","DOI":"10.1016\/j.jhep.2010.12.032"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Efe\u00a0C, Hagstr\u00f6m\u00a0H, Ytting\u00a0H et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2017; 15: 1950\u20131956.e1. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28603052&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.cgh.2017.06.001","DOI":"10.1016\/j.cgh.2017.06.001"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Pape\u00a0S, Nevens\u00a0F, Verslype\u00a0C et al. Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience. Eur J Gastroenterol Hepatol 2020; 32: 727\u201332. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31658173&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FMEG.0000000000001580","DOI":"10.1097\/MEG.0000000000001580"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Muratori\u00a0P, Fabbri\u00a0A, Lalanne\u00a0C et al. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol 2015; 27: 1175\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26148248&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FMEG.0000000000000424","DOI":"10.1097\/MEG.0000000000000424"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Bittencourt\u00a0PL, Farias\u00a0AQ, Porta\u00a0G et al. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol 2008; 42: 300\u20135. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18223493&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FMCG.0b013e31802dbdfc","DOI":"10.1097\/MCG.0b013e31802dbdfc"},{"key":"ref=24","unstructured":"Haraldsplass Diakonale Sykehus. Nasjonalt nettverk for autoimmune leversykdommer. https:\/\/www.haraldsplass.no\/helsefaglig\/forskning-og-utvikling\/nasjonalt-nettverk-for-autoimmune-leversykdommer Lest 28.4.2021."},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Braga\u00a0A, Vasconcelos\u00a0C, Braga\u00a0J. Autoimmune hepatitis and pregnancy. Best Pract Res Clin Obstet Gynaecol 2020; 68: 23\u201331. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32376296&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.bpobgyn.2020.03.007","DOI":"10.1016\/j.bpobgyn.2020.03.007"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:10:52Z","timestamp":1781683852000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2021\/06\/klinisk-oversikt\/diagnostikk-og-behandling-av-autoimmun-hepatitt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,6,29]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.20.1045","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}